Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug 25;376(1-2):81-4.
doi: 10.1016/j.mce.2013.06.007. Epub 2013 Jun 17.

Variable steroid receptor responses: Intrinsically disordered AF1 is the key

Affiliations
Review

Variable steroid receptor responses: Intrinsically disordered AF1 is the key

S Stoney Simons Jr et al. Mol Cell Endocrinol. .

Abstract

Steroid hormones, acting through their cognate receptor proteins, see widespread clinical applications due to their ability to alter the induction or repression of numerous genes. However, steroid usage is limited by the current inability to control off-target, or non-specific, side-effects. Recent results from three separate areas of research with glucocorticoid and other steroid receptors (cofactor-induced changes in receptor structure, the ability of ligands to alter remote regions of receptor structure, and how cofactor concentration affects both ligand potency and efficacy) indicate that a key element of receptor activity is the intrinsically disordered amino-terminal domain. These results are combined to construct a novel framework within which to logically pursue various approaches that could afford increased selectivity in steroid-based therapies.

Keywords: A(max) and EC(50); AF1 domain as a molecular rheostat; Intrinsically disordered domains; Selective receptor modulators (SRMs); Selectivity in controlling gene expression; Steroid receptors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Model for control of cell- and gene-selective transactivation with agonists and SRMs of SRs. Ligand-free SR without chaperone proteins is represented as a three-domain protein consisting of LBD, DBD, and unstructured (red, unlabeled) N-terminal ID/AF1 domains. Ligand (colored geometric shapes) binding modifies LBD conformation and the complex binds to its hormone response element (HRE) on chromatin to form a dimer (only one monomer is illustrated). Gene-selective variations can arise both from near-by or distant interacting, DNA-associated transcription factors (one proximal factor is illustrated; dark blue striped box and shaded oval) (Metivier et al., 2006; Datson et al., 2011; Altintas et al., 2012) and from HRE-induced conformational changes (not shown) (Meijsing et al., 2009; Kim et al., 2013). Differences in cellular concentrations of cofactors (solid shapes), which then bind either simultaneously (as shown) or separately (not illustrated) to the ID/AF1 and LBD to induce varied ID/AF1 structures (different shaped colored ellipses), could yield cell-selective responses. Additional possibilities at this, and the previous step, are indicated by arrows pointing to undesignated structures (…) and subsequent steps. The resultant receptor/steroid/cofactor complexes can then uniquely interact with other transcriptional machinery components to afford varied transcriptional responses. Not indicated are perturbations due to further influences such as protein alterations (e.g., phosphorylation, acetylation, and sumoylation), epigenetic modifications, and other factors/molecules interacting with the receptor and/or illustrated cofactors. SR-mediated gene repression would involve a parallel set of possibilities starting, in most cases, with tethered SR complexes. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

References

    1. Altintas DM, Shukla MS, Goutte-Gattat D, Angelov D, Rouault JP, Dimitrov S, Samarut J. Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells. Mol Endocrinol. 2012;26:1531–1541. - PMC - PubMed
    1. Anbalagan M, Huderson B, Murphy L, Rowan BG. Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal. 2012;10:e001. - PMC - PubMed
    1. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010;17:535–546. - PubMed
    1. Benecke A, Chambon P, Gronemeyer H. Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO. 2000;1:151–157. - PMC - PubMed
    1. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol. 1999;19:8383–8392. - PMC - PubMed

Publication types